Poolbeg Pharma PLC

POLB

GB00BKPG7Z60

Biotechnology & Medical Research

Market Closed - London S.E. Other stock markets 09:05:10 20/06/2025 pm IST			5-day change	1st Jan Change
3.300 ^GBX	0.00%		-5.71%	-53.52%

29/05	Poolbeg Pharma PLC - Shareholder/Analyst Call
27/05	Poolbeg Pharma shares up after US FDA orphan drug designation	AN

Poolbeg Pharma Names Business, Legal Chiefs

Published on 09/11/2023 at 18:15, updated on 09/11/2023 at 18:21

This article is reserved for members

Unlock the article: REGISTER NOW!

100% Free Registration

Already a customer? Log In

Latest news about Poolbeg Pharma PLC

Poolbeg Pharma PLC - Shareholder/Analyst Call	29/05
Poolbeg Pharma shares up after US FDA orphan drug designation	27/05	AN
AIM WINNERS & LOSERS: React Group swings to loss and lowers outlook	27/05	AN
Poolbeg Pharma's POLB 001 Wins Orphan Drug Designation in US	27/05	MT
Poolbeg Granted FDA Orphan Drug Designation For POLB 001	27/05	RE
Poolbeg Pharma Raises GBP5 Million Via Upsized Bookbuild	23/05	MT
Poolbeg upsizes offer; Glenveagh backs outlook	23/05	AN
Poolbeg upsizes fundraise amid strong investor demand	21/05	AN
Poolbeg Pharma Raises GBP4.7 Million via Placing, Subscription	20/05	MT
Poolbeg Pharma PLC Reports Earnings Results for the Full Year Ended December 31, 2024	20/05	CI
Poolbeg Pharma loss widens; launches GBP4 million equity raise	20/05	AN
Poolbeg Pharma Launches GBP4.1 Million Conditional Fundraise via Share Issue	20/05	MT
Earnings Flash (POLB.L) Poolbeg Pharma Reports FY24 Loss GBX-1.16	20/05	MT
Costain wins deal; Focusrite expects revenue hike	20/03	AN
Poolbeg Pharma plc Receives Korean Intellectual Property Office Grant in Korea	20/03	CI
FTSE 100 flat, despite buoyant banks, as US falls	21/02	AN
Retailers lift FTSE 100 after strong sales tonic	21/02	AN
AIM WINNERS & LOSERS: Proteome wins deal; Biome plots AIM exit	21/02	AN
Poolbeg Pharma Says Hookipa Ended Takeover Talks	21/02	MT
FTSE 100 flat as UK data keeps pound above USD1.26	21/02	AN
Poolbeg Pharma shares plummet as Hookipa walks away from possible bid	21/02	AN
StanChart announces buyback as 2024 profit climbs	21/02	AN
Poolbeg Pharma Says Hookipa Terminated Discussions On Proposed Merger	21/02	RE
Hookipa Pharma rules out making offer for Poolbeg Pharma	21/02	AN
Poolbeg Pharma PLC cancelled the acquisition of HOOKIPA Pharma Inc. in a reverse merger transaction.	20/02	CI

Poolbeg Pharma Plc is a United Kingdom-based biopharmaceutical company. The Company is engaged in the development of medicines to address the unmet need for infectious and other prevalent diseases. The Company is involved in the development of a range of pharmaceutical products. Its product pipeline includes POLB 001, POLB 001 Oncology, POLB 001 Influenza, AI Programs, Oral GLP-1R Agonist. Its POLB 001 aims to target the Cytokine Release Syndrome (CRS) associated with many cancer immunotherapy treatments which impacts 70% of patients undergoing CAR T or Bispecific Antibody therapy. The Company uses artificial intelligence to identify infectious disease drug targets & treatments. Its Oral GLP-1R Agonist is a delivery system which offers a scalable, natural, Generally Regarded As Safe (GRAS) approved solution for the oral delivery of metabolic peptide cargo to specific areas of the gut and into systemic circulation for the treatment of diabetes, obesity and other metabolic diseases.

Employees

Sector

Biotechnology & Medical Research

Calendar

06:30pm - Annual General Meeting

More about the company